Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
421
-
422
-
423
Simultaneous ablation of Syt1 and Syt7 decreases the RRP size at inhibitory synapses: Rescue by WT but not mutant Syt1 or Syt7.
Published 2015“…Recordings were performed in the presence of 1 μM tetrodotoxin, 20 μM CNQX, and 50 μM AP5 to isolate inhibitory currents. <b>B.</b> Simultaneous ablation of Syt1 and Syt7 decreases the RRP size of inhibitory synapses in a manner that is rescued by WT Syt7 (Syt1<sup>WT</sup>) but not Syt7 with mutations in the top C2 domain sequences containing the Syt7 Ca<sup>2+</sup> binding sites (Syt7<sup>C2A</sup>*<sup>B</sup>*). …”
-
424
-
425
-
426
-
427
-
428
Klf5 expression is down-regulated in the ruptured human and experimental AAA.
Published 2020Subjects: -
429
-
430
-
431
-
432
Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation.
Published 2013“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
-
433
Inhibition of GLS1 decreases the proportion of CCR6 and CXCR3 expressing CD4<sup>+</sup> T cells.
Published 2016“…BPTES and 968 significantly decrease the proportion of CCR6 expressing cells under normoxia both at day 3 and 5, whereas 968 but not BPTES decrease the proportion of CCR6 expressing cells under hypoxia both at day 3 and 5. …”
-
434
-
435
-
436
-
437
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…Treatment with Gemcitabine or Cisplatin alone decreased tumor volume to a higher (p < 0.05) extent than OCA alone. …”
-
438
-
439
-
440